US Bancorp DE Has $462,000 Holdings in Arcellx, Inc. (NASDAQ:ACLX)

US Bancorp DE cut its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 20.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,023 shares of the company’s stock after selling 1,580 shares during the quarter. US Bancorp DE’s holdings in Arcellx were worth $462,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ACLX. RA Capital Management L.P. raised its holdings in shares of Arcellx by 15.4% in the 3rd quarter. RA Capital Management L.P. now owns 1,851,479 shares of the company’s stock valued at $154,617,000 after purchasing an additional 247,465 shares during the period. First Turn Management LLC acquired a new position in shares of Arcellx during the 3rd quarter worth approximately $17,896,000. Janus Henderson Group PLC boosted its position in shares of Arcellx by 5.7% during the 3rd quarter. Janus Henderson Group PLC now owns 2,011,950 shares of the company’s stock worth $168,026,000 after acquiring an additional 109,332 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Arcellx by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 974,967 shares of the company’s stock worth $81,434,000 after acquiring an additional 39,781 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Arcellx by 67.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 79,936 shares of the company’s stock valued at $6,675,000 after purchasing an additional 32,119 shares during the last quarter. 96.03% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Christopher Heery sold 3,301 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $79.55, for a total value of $262,594.55. Following the completion of the sale, the insider now owns 35,517 shares of the company’s stock, valued at approximately $2,825,377.35. This represents a 8.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rami Elghandour sold 38,300 shares of the company’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the completion of the sale, the insider now directly owns 149,186 shares of the company’s stock, valued at $9,252,515.72. This trade represents a 20.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,370 shares of company stock valued at $4,189,641 over the last quarter. Company insiders own 6.24% of the company’s stock.

Wall Street Analysts Forecast Growth

ACLX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Arcellx in a research note on Tuesday, December 10th. Barclays raised shares of Arcellx to a “strong-buy” rating in a research note on Friday, November 29th. UBS Group lifted their target price on shares of Arcellx from $106.00 to $114.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Finally, Needham & Company LLC restated a “buy” rating and issued a $105.00 price target on shares of Arcellx in a report on Monday, December 9th. Thirteen analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $108.46.

Arcellx Stock Performance

Arcellx stock opened at $72.72 on Thursday. The stock has a market cap of $4.00 billion, a PE ratio of -102.42 and a beta of 0.32. Arcellx, Inc. has a fifty-two week low of $47.88 and a fifty-two week high of $107.37. The firm’s 50-day simple moving average is $67.15 and its 200 day simple moving average is $77.69.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $15.27 million during the quarter, compared to the consensus estimate of $27.42 million. As a group, analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).